Bicocca Open Archive

Logo unimib boa
BIDOLI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.924
AS - Asia 6.148
EU - Europa 4.354
SA - Sud America 950
AF - Africa 135
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 4
Totale 22.527
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.028
SG - Singapore 2.355
HK - Hong Kong 1.151
CN - Cina 1.113
IT - Italia 1.106
CA - Canada 820
RU - Federazione Russa 820
BR - Brasile 702
IE - Irlanda 614
VN - Vietnam 537
DE - Germania 491
SE - Svezia 461
IN - India 198
GB - Regno Unito 180
FR - Francia 177
BD - Bangladesh 174
UA - Ucraina 122
FI - Finlandia 95
AR - Argentina 93
TR - Turchia 76
AT - Austria 75
ID - Indonesia 75
IQ - Iraq 74
PK - Pakistan 60
JP - Giappone 58
SA - Arabia Saudita 45
MX - Messico 43
PH - Filippine 42
DK - Danimarca 39
ZA - Sudafrica 39
CO - Colombia 36
KR - Corea 36
ES - Italia 35
NL - Olanda 33
VE - Venezuela 33
EC - Ecuador 30
PL - Polonia 25
UZ - Uzbekistan 25
BE - Belgio 19
JO - Giordania 17
CL - Cile 14
NP - Nepal 14
PY - Paraguay 14
KE - Kenya 12
MA - Marocco 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
JM - Giamaica 11
PE - Perù 11
AU - Australia 10
EG - Egitto 10
DZ - Algeria 8
ET - Etiopia 8
IR - Iran 8
KZ - Kazakistan 8
MY - Malesia 8
TN - Tunisia 8
LB - Libano 7
TH - Thailandia 7
AZ - Azerbaigian 6
RO - Romania 6
SN - Senegal 6
AL - Albania 5
AO - Angola 5
BA - Bosnia-Erzegovina 5
BO - Bolivia 5
IL - Israele 5
MU - Mauritius 5
PS - Palestinian Territory 5
RS - Serbia 5
AM - Armenia 4
BG - Bulgaria 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
LT - Lituania 4
MN - Mongolia 4
NG - Nigeria 4
PA - Panama 4
TW - Taiwan 4
BY - Bielorussia 3
CH - Svizzera 3
CI - Costa d'Avorio 3
GA - Gabon 3
GR - Grecia 3
LV - Lettonia 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
BH - Bahrain 2
CG - Congo 2
CZ - Repubblica Ceca 2
EU - Europa 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
IS - Islanda 2
MD - Moldavia 2
MM - Myanmar 2
Totale 22.492
Salva come PNG Salva come JPEG
Città #
Singapore 1.333
Ann Arbor 1.331
Hong Kong 1.114
Ashburn 971
Fairfield 850
Toronto 720
San Jose 618
Dublin 606
Woodbridge 481
Wilmington 435
Seattle 389
Chandler 372
Houston 329
Milan 328
Cambridge 321
New York 312
Frankfurt am Main 296
Princeton 248
Chicago 225
Beijing 221
The Dalles 216
Santa Clara 174
Jacksonville 169
Ho Chi Minh City 158
Los Angeles 153
Shanghai 136
Hanoi 125
Altamura 122
Lauterbourg 119
Lawrence 118
Dallas 107
Rome 102
Council Bluffs 84
Moscow 78
San Diego 73
Helsinki 68
Dearborn 63
São Paulo 56
Jakarta 51
Vienna 51
Buffalo 49
Andover 44
Boardman 44
London 40
Guangzhou 39
Turin 37
Baghdad 34
Nanjing 33
Tokyo 33
Hefei 32
Orem 30
Rio de Janeiro 30
Salt Lake City 30
Hangzhou 29
Munich 29
Haiphong 28
Nuremberg 28
Pune 26
Dhaka 25
Ottawa 25
Washington 25
Columbus 24
Falls Church 23
Da Nang 22
Dong Ket 22
Lahore 22
Seoul 22
Riyadh 21
Tashkent 20
Chennai 19
San Francisco 19
Boston 18
Brussels 18
Norwalk 18
Atlanta 17
Johannesburg 17
Naples 17
Phoenix 17
Tianjin 17
Montreal 16
Mumbai 16
Amman 15
Jinan 15
Amsterdam 14
Tampa 14
Warsaw 14
Brasília 13
Elk Grove Village 13
Hebei 13
Redmond 13
Zhengzhou 13
Brooklyn 12
Changsha 12
Guayaquil 12
Istanbul 12
Jeddah 12
Karachi 12
Lachine 12
Torre Del Greco 12
Denver 11
Totale 15.042
Salva come PNG Salva come JPEG
Nome #
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 451
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 405
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 400
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 389
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 374
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 354
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 344
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 325
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 315
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 314
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 311
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 309
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 296
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 295
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 275
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 272
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 266
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 252
When progressive dysphagia could be related to an “old friend” – a case report 245
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 240
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 237
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 233
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 232
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 222
Novel cytotoxic chemotherapies in small cell lung carcinoma 221
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 220
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 211
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 209
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 208
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 201
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 200
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 197
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer 196
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 196
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 194
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 194
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 193
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 191
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 191
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 190
Focus on nivolumab in NSCLC 190
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 189
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 187
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 185
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 184
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 183
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 175
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 175
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 172
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 172
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 170
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 169
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 169
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 168
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 167
Drugs ten years later: epirubicin 167
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 167
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 167
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 167
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 166
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 163
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 160
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 159
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial 155
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 154
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 154
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 154
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 154
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 153
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 153
Pilot study with adriamycin and ifosfamide in small cell lung cancer 152
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 151
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 150
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 150
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 148
A new race against lung cancer 146
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 146
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 145
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 145
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 144
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 143
Oxaliplatin doublets in non-small cell lung cancer: A literature review 142
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 142
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) [Trattamento con Gefitinib nei pazienti anziani o con scarso performance status (PS), affetti da carcinoma polmonare non a piccole cellule (NSCLC)] 142
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 142
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 142
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients 142
Targeted therapies and immunotherapy in non-small-cell lung cancer 140
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 140
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 140
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 139
Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity 138
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 137
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 136
Isolated cardiac metastasis from squamous cell esophageal cancer 135
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 133
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 133
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial 132
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer 132
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 131
Totale 19.854
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.444
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.444
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021190 0 0 0 0 0 0 0 0 0 0 0 190
2021/20221.233 107 156 159 71 40 86 79 62 67 53 96 257
2022/20231.894 273 635 127 134 83 303 33 99 131 21 30 25
2023/20241.867 32 36 59 59 272 498 377 101 205 14 17 197
2024/20253.752 219 500 198 171 301 132 213 80 463 555 277 643
2025/20268.851 783 521 464 642 908 451 1.591 452 710 572 965 792
Totale 23.135